Breaking News

Collegium Purchases BioDelivery Sciences International in All-Cash Deal

Transaction is valued at $5.60 per share representing a total equity value of $604 million.

Author Image

By: Charlie Sternberg

Associate Editor

BioDelivery Sciences International Inc., a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, has entered into a definitive merger agreement for Collegium Pharmaceutical Inc. to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction.   This corresponds to a total equity value of approximately $604 million (on a fully diluted basis). The merger agreement has been unanimously approved by the Board of D...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters